"Follow-On" Biologics Framework Development Will Become More Public Process, FDA's Kweder Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency is still struggling with scientific issues, the Office of New Drugs deputy director says. A delay in the public comment process should not be perceived as FDA "just being secretive."
You may also be interested in...
Follow-On Biologics Guidance Delayed, Agency Tells BIO
Broad scope and broad "interest" in the topic mean it will take FDA longer than expected to complete work on the highly anticipated guidance, Acting Deputy Commissioner Woodcock says. The guidance will include an "inventory" of different ways protein products have been regulated by the agency.
Follow-On Biologics Guidance Delayed, Agency Tells BIO
Broad scope and broad "interest" in the topic mean it will take FDA longer than expected to complete work on the highly anticipated guidance, Acting Deputy Commissioner Woodcock says. The guidance will include an "inventory" of different ways protein products have been regulated by the agency.
FDA Follow-On Biologics Guidance Will Have Broad Scope, But Not "Break New Ground"
Acting CDER Director Galson says draft guidance will be out this spring. Scientific principles will cover range of biologics therapies – but scientific and legal obstacles will limit impact to a relative handful of products.